Get started
Author

Mourad Amrane

Observed names: Amrane, Mourad, M AMRANE, M Amrane, M. Amrane
Institution: Santen (France)
ORCID: 0000-0001-7661-5755
Observed ORCID: 0000-0001-7661-5755
OpenAlex ID: A5041463616
Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial
2016 · Andrea Leonardi, Gysbert Van Setten, et al. · European Journal of Ophthalmology · 194
PDF
Relevance of Lipid-Based Products in the Management of Dry Eye Disease
2017 · Jean-Sébastien Garrigue, Mourad Amrane, et al. · Journal of Ocular Pharmacology and Therapeutics · 124
PDF
A Randomized Study of the Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in Treatment of Moderate to Severe Dry Eye
2017 · Christophe Baudouin, Francisco C. Figueiredo, et al. · European Journal of Ophthalmology · 112
A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis
2018 · Andrea Leonardi, Serge Doan, et al. · Ophthalmology · 95
PDF
One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease
2017 · Christophe Baudouin, Maite Sainz de la Maza, et al. · European Journal of Ophthalmology · 92
PDF
Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies
2018 · Andrea Leonardi, Elisabeth M Messmer, et al. · British Journal of Ophthalmology · 67
PDF
Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease – A randomised comparative study
2014 · M. Amrane, C. Creuzot-Garcher, et al. · Journal Français d Ophtalmologie · 54
Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease
2017 · Françoise Brignole-Baudouin, Luisa Riancho, et al. · Investigative Ophthalmology & Visual Science · 52
Efficacy and Safety of a Cationic Emulsion in the Treatment of Moderate to Severe Dry Eye Disease: A Randomized Controlled Study
2016 · Pierre-Yves Robert, Béatrice Cochener, et al. · European Journal of Ophthalmology · 47
PDF
Twelve-Month Results of Cyclosporine A Cationic Emulsion in a Randomized Study in Patients With Pediatric Vernal Keratoconjunctivitis
2019 · Dominique Bremond-Gignac, Serge Doan, et al. · American Journal of Ophthalmology · 45
PDF
Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease
2020 · Philippe Daull, Mourad Amrane, et al. · Journal of Ocular Pharmacology and Therapeutics · 40
PDF
Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study
2018 · Marc Labetoulle, Andrea Leonardi, et al. · Clinical Therapeutics · 30
PDF
Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
2018 · Pierre-Jean Pisella, Marc Labetoulle, et al. · Clinical ophthalmology · 30
PDF
Pan-European survey of the topical ocular use of cyclosporine A
2017 · A. Labbé, C. Baudouin, et al. · Journal Français d Ophtalmologie · 23
Novasorb® Cationic Nanoemulsion and Latanoprost: The Ideal Combination for Glaucoma Management?
2017 · Philippe Daull, Mourad Amrane, et al. · Journal of Eye Diseases and Disorders · 21
PDF
First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure
2010 · Philippe Denis, Christophe Baudouin, et al. · BMC Ophthalmology · 21
PDF
Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials
2022 · Andrea Leonardi, Serge Doan, et al. · Eye · 12
PDF
Poor Correlation Between Dry Eye Disease (DED) Signs and Symptoms in a Phase III Randomized Clinical Trial
2011 · Michael A. Lemp, Christopher Baudouin, et al. · Investigative Ophthalmology & Visual Science · 12
A phase 2, randomized study evaluating the safety and efficacy of Catioprost® (unpreserved latanoprost 0.005% emulsion) compared to Travatan Z® in subjects with glaucoma and ocular surface disease
2011 · D ISMAIL, M AMRANE, et al. · Acta Ophthalmologica · 10
NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis
2023 · Andrea Leonardi, Pierre-Jean Pisella, et al. · Clinical Therapeutics · 7
PDF
The Effect of Ikervis® (1 mg/mL Ciclosporin cationic emulsion) on severe keratitis in patients with dry eye disease participating in a phase III study
2015 · A. Leonardi, M. Labetoulle, et al. · Acta Ophthalmologica · 6
The effect of Cyclokat® (Unpreserved 0.1% cyclosporine cationic Emulsion) on corneal involvement in patients with moderate to severe dry eye disease participating in a phase III, multicenter, randomized, controlled, double-masked, clinical trial
2011 · Ronald Buggage, Mourad Amrane, et al. · European Journal of Ophthalmology · 6
Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease
2024 · Marc Labetoulle, Gerhard Garhöfer, et al. · Acta Ophthalmologica · 4
PDF
Patients with Moderate to Severe Dry Eye Disease in Routine Clinical Practice in the UK - Physician and Patient’s Assessments
2015 · Mourad Amrane, Alexandre Civet, et al. · Investigative Ophthalmology & Visual Science · 4
Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study
2024 · Jason Bacharach, Eugene B. McLaurin, et al. · Journal of Ocular Pharmacology and Therapeutics · 3
Works count: 48
Citation count: 1,120
H-index: 16
I10-index: 19
Year
Topic
Type